William Blair Maintains Buy Rating on Exelixis Following Positive Cancer Trial Results, Despite Safety Concerns
William Blair analyst Andy Hsieh reaffirms Buy rating on EXEL stock after Phase III trial shows zanzalintinib combination therapy improves survival in metastatic colorectal cancer patients.